SCS
SCS operates in Biotechnology.
SCS (SCS) - Total Assets
Latest total assets as of June 2024: zł12.92 Million PLN
Based on the latest financial reports, SCS (SCS) holds total assets worth zł12.92 Million PLN as of June 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
SCS - Total Assets Trend (2015–2023)
This chart illustrates how SCS’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
SCS - Asset Composition Analysis
Current Asset Composition (December 2023)
SCS's total assets of zł12.92 Million consist of 5.7% current assets and 94.3% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0.1% |
| Accounts Receivable | zł146.81K | 1.1% |
| Inventory | zł586.48K | 4.3% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł4.95 Million | 36.4% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2015–2023)
This chart illustrates how SCS's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SCS's current assets represent 5.7% of total assets in 2023, an increase from 3.1% in 2015.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2023, up from 0.0% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 36.0% of total assets, an increase from 12.0% in 2015.
- Asset Diversification: The largest asset category is intangible assets at 36.4% of total assets.
SCS Competitors by Total Assets
Key competitors of SCS based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Macrogen Inc
KQ:038290
|
Korea | ₩341.60 Billion |
|
Panagene Inc
KQ:046210
|
Korea | ₩101.91 Billion |
|
Cell Biotech Co. Ltd
KQ:049960
|
Korea | ₩134.57 Billion |
|
Bioneer Corporation
KQ:064550
|
Korea | ₩376.52 Billion |
|
MEDIPOST Co. Ltd
KQ:078160
|
Korea | ₩374.57 Billion |
|
Biotoxtech Co. Ltd
KQ:086040
|
Korea | ₩132.45 Billion |
|
Peptron Inc
KQ:087010
|
Korea | ₩183.74 Billion |
|
Hadasit Bio
TA:HDST
|
Israel | ILA14.67 Million |
SCS - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - SCS generates 0.03x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - SCS is currently not profitable relative to its asset base.
SCS - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.59 | 5.05 | 0.12 |
| Quick Ratio | 0.58 | 1.23 | 0.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł543.91K | zł 649.24K | zł -5.81 Million |
SCS - Advanced Valuation Insights
This section examines the relationship between SCS's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -8.1% |
| Total Assets | zł13.61 Million |
| Market Capitalization | $909.17 USD |
Valuation Analysis
Below Book Valuation: The market values SCS's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: SCS's assets decreased by 8.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for SCS (2015–2023)
The table below shows the annual total assets of SCS from 2015 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | zł13.61 Million | -8.06% |
| 2022-12-31 | zł14.80 Million | -13.35% |
| 2021-12-31 | zł17.08 Million | +14.94% |
| 2020-12-31 | zł14.86 Million | -13.74% |
| 2019-12-31 | zł17.23 Million | -10.08% |
| 2018-12-31 | zł19.16 Million | -9.84% |
| 2017-12-31 | zł21.25 Million | +0.44% |
| 2016-12-31 | zł21.16 Million | +0.43% |
| 2015-12-31 | zł21.07 Million | -- |